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ABSTRACT
Itraconazole is a triazole broad-spectrum antifungal agent that can be given as capsules, oral solution or
intravenous solution. Bioavailability in neutropenic patients is different between capsules (c. 23%) and
oral solution (c. 55%). A dose–response relationship has been established for the use of itraconazole in
antifungal prophylaxis: HPLC-determined trough concentrations of itraconazole need to be above
500 ng ⁄mL for effective prevention of invasive Aspergillus infections. A meta-analysis of 13 randomised
clinical trials and 3597 neutropenic patients with haematological malignancies has demonstrated a 53%
reduction in the incidence of invasive Aspergillus infections with a sufﬁcient dose of itraconazole. Two
randomised clinical trials evaluated itraconazole for empirical antimycotic therapy in neutropenic
patients with persisting fever despite broad-spectrum antibiotic therapy in comparison to conventional
amphotericin B. Both demonstrated signiﬁcantly reduced nephrotoxicity and at least comparable
efﬁcacy. In conclusion, itraconazole should be regarded as the standard for antifungal prophylaxis in
high-risk patients and a valuable therapeutic option for empirical antifungal therapy in these patients.
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INTRODUCTION
Itraconazole is a broad-spectrum triazole anti-
fungal agent that was ﬁrst introduced for use in
patients with invasive fungal infections in 1987,
when amphotericin B and ﬂuconazole (new at
that time) were the limited options for effective
systemic therapy [1,2]. The form in which
itraconazole was ﬁrst used clinically was a
capsule containing sugar-coated pellets. This
was extremely successful in the treatment of
fungal infections of skin and nails [3] but,
despite some initially encouraging results, did
not deliver sufﬁciently reliable bioavailability in
neutropenic patients. The achlorhydria, mucos-
itis, nausea and anorexia that complicate the
management of these patients reduce signiﬁ-
cantly the intake and absorption of the drug
[4–6]. It is estimated that only about 22% of the
substance is taken up by the patient in this
clinical situation [7].
The formulation of the drug changed with the
production of an oral solution of this highly
lipophilic drug. Establishing a new principle in
drug galenics, b-hydroxy-propyl-cyclodextrin, an
oligosaccharide formed from seven glucose mol-
ecules, was used to incorporate itraconazole into
an aqueous solution that could be swallowed and
absorbed or infused intravenously [8–10]. Exter-
nally hydrophilic and internally lipophilic, cyclo-
dextrin brings itraconazole into the systemic
circulation, where it separates instantaneously.
Cyclodextrin is inert and undergoes renal elimin-
ation without any metabolism.
With these new oral and intravenous solutions,
new trials were designed to evaluate the efﬁcacy
of itraconazole in antimycotic prophylaxis, in
empirical antifungal therapy and, to a lesser
extent, in the treatment of proven invasive fungal
infections. At the same time, clearer data on
the drug’s dose–response relationship became
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available and explained some of the earlier
disappointments. This article reviews the most
important pharmacological and clinical data on
itraconazole and attempts to deﬁne its role in
today’s much larger armamentarium of antifun-
gal agents (Table 1).
CLINICAL PHARMACOLOGY AND
PHARMACODYNAMICS
The bioavailability of itraconazole capsules in
neutropenic patients has been estimated at 22%,
while the oral solution achieves about 55%
bioavailability [7,11,12]. Several papers have
reviewed itraconazole’s pharmacokinetic proper-
ties in detail [3,7,10,13–17]. The elimination half-
life after a single dose is about 24 h, which
increases to an apparent elimination half-life of
34 h in the steady state. Itraconazole is highly
lipophilic and therefore it has a large volume of
distribution (11 L ⁄ kg). This means that without a
loading dose it may take up to 14 days to achieve
steady state [6,7].
Itraconazole’s protein-binding fraction is high
(99%), and therefore it cannot be removed by
haemodialysis [18–20]. The drug is metabolised
in the liver by the cytochrome P450 pathway,
and it is a substrate and a strong inhibitor of
the isoenzyme 3A4, which is an important
regulator of drug elimination pathways. Safe
use of itraconazole requires careful attention to
its interactions with other drugs. In cases of renal
insufﬁciency, dose reduction of oral itraconazole
is not necessary, whereas the intravenous solu-
tion is contraindicated in patients with a creat-
inine clearance below 30 mL ⁄min. In patients
with minor or moderate degrees of hepatic
insufﬁciency, dosing of itraconazole does not
need to be changed; the standard dose can be
used initially and then adapted according to the
drug monitoring results (recommended range
500–2000 ng ⁄mL itraconazole; see below) [17].
Itraconazole is the only azole that forms an
active metabolite, hydroxy-itraconazole, which
has the same spectrum of antimicrobial activity
as the parent compound [5]. In the steady
state, this metabolite is found at concentrations
approximately two-fold those of the parent
compound, indicating that total serum antifun-
gal activity is much higher than that corres-
ponding to the itraconazole concentration
alone.
Itraconazole inhibits 14-a-demethylase, the
rate-limiting enzyme for the synthesis of ergos-
terol, which is an important component of the
fungal cell membrane [6]. While its effects on
Candida spp. are fungistatic, it can achieve fungi-
cidal activity on Aspergillus spp. at higher doses
[21,22].
DEFINITION OF THE TARGET DRUG
CONCENTRATION
An early study of the efﬁcacy of antifungal
prophylaxis with itraconazole in neutropenic
patients found a lower rate of invasive fungal
infections in patients who had serum concentra-
tions above 250 ng ⁄mL for at least 2 weeks [23]. In
Table 1. The role of itraconazole in
antifungal treatment strategies Clinical problem Role of itraconazole References
Prevention of invasive
fungal infections
Only antifungal agent with clear
evidence that it prevents invasive
fungal infections, including










Bioavailability Available as oral or intravenous
solution (loading dose and drug
monitoring required)
[7,11,34,54]
Drug–drug interaction Co-administration with drugs
that are metabolised by
cytochrome P450 3A4
to be avoided or adjusted for
(Hurle´, this issue)
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the absence of any further research into the
‘effective’ level, a trough concentration of 250
ng ⁄mL itraconazole (measured by HPLC) has
been considered to be optimal [16]. The additional
concentration of hydroxy-itraconazole gives a
total serum concentration of c. 750 ng ⁄mL (250
ng ⁄mL itraconazole plus 500 ng ⁄mL hydroxy-
itraconazole), which is probably not sufﬁcient for
most Aspergillus spp., for which MICs of c. 800–
1000 ng ⁄mL have been determined [24,25]. An
in-vivo model of an experimental Aspergillus
infection in immunosuppressed rabbits suggested
that higher concentrations are necessary to
achieve optimal reduction of the number of
pulmonary colony-forming Aspergillus conidia
[26]. When establishing the NCCLS recommen-
dations on breakpoints for antifungal susceptibil-
ity testing, Rex et al. analysed itraconazole trough
concentrations and response in patients with
AIDS and oesophageal candidiasis [27]. In infec-
tions due to Candida spp. for which higher MICs
were determined, clinical response rates were
higher in patients when trough concentrations
greater than 500 ng ⁄mL were achieved.
Following on from these studies, we have
analysed data from a cohort of consecutive
neutropenic patients with haematological malig-
nancies who have received myelosuppressive
therapy and antifungal prophylaxis with itracon-
azole at increasing doses. Comparing itraconazole
trough concentrations in patients with break-
through invasive mycoses with those in patients
who did not develop these infections, we dem-
onstrated that the higher cut-off value
(500 ng ⁄mL) was more likely to be protective
against systemic fungal infection. In a subsequent
case-control study, we compared itraconazole
levels in 41 patients with invasive fungal infec-
tions (mostly proven or suspected invasive mould
infections, with three invasive Candida infections)
during antifungal prophylaxis with levels in 81
controls without an invasive fungal infection,
matched for underlying disease and time of
treatment. An itraconazole trough concentration
above 500 ng ⁄mL was a statistically signiﬁcant
protective factor (OR 0.32, p 0.010), whereas a
trough concentration above 250 ng ⁄mL was not
(OR 0.39, p 0.084). Therefore, a trough concentra-
tion above 500 ng ⁄mL (ideally around
1000 ng ⁄mL) should be considered as a target




The inability of current diagnostic methods (clin-
ical, culture- or non-culture-based, radiological)
to provide a timely diagnosis [28] and the high
mortality of invasive fungal infections in neu-
tropenic patients [29,30] have led to an intensive
search for alternative therapeutic strategies that
do not depend on diagnostic measures. The most
frequently used are empirical antifungal therapy,
which is discussed below, and antifungal pro-
phylaxis. We have recently reviewed the current
data on antifungal prophylaxis with itraconazole
[31,32], and focus here on a concise summary of
the available evidence and current controversies
regarding this concept.
Fluconazole is still the most frequently used
drug in antifungal prophylaxis, despite an aston-
ishing lack of evidence to support this practice
and its well-known intrinsic absence of activity
against Aspergillus spp. Kanda et al. have pro-
duced a very clear meta-analysis of 16 studies
with 3734 patients who received ﬂuconazole in
randomised trials of antifungal prophylaxis [33].
They clearly demonstrated that ﬂuconazole is
only active at higher doses and in patients
receiving allogeneic stem-cell transplantation;
patients with acute leukaemia did not proﬁt from
prophylaxis with this drug. The role of itracon-
azole and ﬂuconazole in the setting of allogeneic
stem-cell transplantation is reviewed elsewhere in
this supplement.
Our meta-analysis of 13 trials and 3597 patients
unequivocally shows that the use of itraconazole
in neutropenic patients with haematological
malignancies and at sufﬁciently high doses
(i.e., at least 400 mg ⁄day oral solution or
200 mg ⁄day intravenous solution) results in a
statistically signiﬁcant, 53% reduction in the
relative risk of proven invasive fungal infections
[31]. This meta-analysis showed, for the ﬁrst time,
that a drug could reduce the risk of invasive
Aspergillus infections signiﬁcantly by 46% and the
mortality from invasive fungal infections by 45%.
Antifungal prophylaxis with itraconazole is
well-tolerated, with the exception of a higher rate
of nausea and vomiting due to the cyclodextrin
content of the oral solution and a higher rate of
hypokalaemia [32,34]. Severe hepatic and renal
toxicity was seen in one trial, where relatively
high doses of itraconazole were associated with
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prolonged and presumably toxic levels of the
cytotoxic drug cyclophosphamide, which was
given concomitantly with the itraconazole, as
conditioning therapy prior to stem-cell transplan-
tation, and which is metabolised by cytochrome
P450 isoenzymes [35,36]. This additional toxicity
was no longer observed when the start of itrac-
onazole treatment was delayed until stem-cell
re-infusion, which allows signiﬁcant clearance of
cyclophosphamide metabolites. We are not aware
of any reports of such an interaction with any
other alkylators, anthracyclines or antimetabo-
lites, but itraconazole cannot be given close to the
time of administration of vinca alkaloids, because
of an interaction leading to the risk of potentially
fatal neurotoxicity.
Many other drugs interact with itraconazole,
and the prescribing physicians should be aware of
these interactions and the various ways of min-
imising their effects. These interactions are sum-
marised in a previous review by one of the
authors [6] and elsewhere in this supplement.
These interactions can be divided into those
affecting the level of itraconazole and those
affecting the level of the interacting drug. Meta-
bolism of itraconazole is induced by rifampicin,
carbamazepine, phenytoin, phenobarbitone and
isoniazid. Itraconazole reduces the rate of meta-
bolism of cyclosporin, tacrolimus and digoxin.
Adjustment of the doses of itraconazole or these
interacting drugs may achieve safe and effective
levels of either. Concomitant use of midazolam,
triazolam, cisapride (no longer available under
licence in some EU countries), terfenadine and
astimazole should be avoided, however, because
itraconazole can rapidly induce clinically danger-
ous levels of these drugs. Concomitant use with
calcium channel blockers should also be avoided,
or at least the QT interval should be monitored
carefully if concomitant use is unavoidable.
Coumarin derivatives can also be potentiated, so
the International Normalized Ratio (INR) should
be monitored carefully in patients needing war-
farin and itaconazole simultaneously.
As nausea and vomiting are common side-
effects of both leukaemia-related myelosuppres-
sive chemotherapy and the conditioning therapy
of full intensity used prior to stem-cell transplan-
tation, oral intake of drugs cannot always be
maintained. Therefore, the availability of an intra-
venous formulation of itraconazole allows more
consistent bioavailability and compliance, as
demonstrated by the study of Winston et al.
[37,38].
The most important criticism of antifungal
prophylaxis is that it is unselective. All patients
receive the drug, whereas only c. 15% (the aver-
age incidence in neutropenic patients with haem-
atological malignancies in the untreated control
arms of our meta-analysis) would have eventually
developed an invasive fungal infection. The bal-
ance of beneﬁt vs. risk is weighted in favour of
prophylaxis, however, by the combination of the
devastating effects of an invasive infection and
the relatively low toxicity of the azoles. Further-
more, an analysis of the number-to-treat, which
greatly depends on the baseline risk, showed that
among patients with a 15% risk of invasive fungal
infections, 13 patients have to be treated to avoid
one invasive fungal infection [31]. This suggests
an additional cost–effect balance in favour of
prophylaxis with itraconazole against invasive
fungal infections [32,37,39].
Antifungal prophylaxis has been criticised
because there is no evidence that it can reduce
overall mortality. Most studies, however, have
not extended their follow-up period long enough
to observe such an effect, which would probably
be very difﬁcult to separate from other factors
such as the underlying disease and its therapy.
Considering the immense rate of morbidity and
the cost of invasive fungal infections, however,
the prevention of these infections is a target that is
worthwhile in its own right.
In conclusion, we recommend the use of anti-
fungal prophylaxis with itraconazole in all
patients with haematological malignancies who
have received myelosuppressive chemotherapy
with an expected duration of neutropenia of more
than 10 days, except for those who are given
vinca alkaloids.
EMPIRICAL ANTIFUNGAL THERAPY
The results of two randomised trials in the 1980s
led to the conventional use of intravenous anti-
fungal therapy in neutropenic patients who had
persistent fever despite broad-spectrum antibiotic
therapy for 3–5 days. This practice probably
accounts for the greatest part of spending on
antifungal drugs [40].
After the initial proof of concept [41,42], a series
of studies tested different antifungal agents, with
defervescence as the main outcome. This
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endpoint was, however, rejected by the regulating
authorities, and colleagues in the USA then
proposed a combined outcome score [43–45] that
consists of ﬁve elements and that has been used
since. No comparative study so far has been
sufﬁciently powered, however, to demonstrate
differences in either the rate of breakthrough
invasive fungal infections following the start of
systemic antifungal therapy or the overall
response to that therapy.
Itraconazole has been tested in two clinical
trials that have used conventional amphotericin B
as a comparator [46,47]. The basic characteristics
of these trials have many comparable features.
Important differences were that a treatment
crossover was allowed and that patients who
underwent allogeneic stem-cell transplantation,
as well as patients with pneumonia, were inclu-
ded in the German trial [47].
Both trials demonstrated a comparable rate of
breakthrough invasive fungal infections with
amphotericin B, but a considerably lower rate of
treatment discontinuation and nephrotoxicity.
Therefore, itraconazole is a valuable alternative
to conventional amphotericin B in empirical
antifungal therapy in neutropenic patients with
persistent fever [48,49].
PHARMACO-ECONOMIC ASPECTS
A calculation by Tolley et al., presented at a
meeting in 2003, demonstrated that the total cost
of an antifungal strategy as used in the Winston
study was £4789 (7057 euros) with itraconazole
and £9792 (14 428 euros) with ﬂuconazole. The
difference is explained mainly by the better
efﬁcacy of itraconazole. Also, van Gool et al.
performed a similar economic analysis of empir-
ical antifungal therapy based on the results of the
trials of Boogaerts et al. and Walsh et al., and
found that the total cost of treatment, including
hospital stay, was lowest with the use of itracon-
azole [44,46,50].
CONCLUSIONS
An evidence-based recommendation for the use
of itraconazole (in sufﬁcient doses of the oral or
intravenous solution) is made for its application
in antifungal prophylaxis for high-risk patients
where invasive fungal infections, including those
caused by Aspergillus spp., can be reduced by
c. 50%. Therefore, we regard itraconazole pro-
phylaxis as the standard therapy in patients at
high risk for invasive fungal infections.
Several choices are available for empirical
antifungal therapy. Besides itraconazole, liposom-
al amphotericin B and caspofungin have demon-
strated non-inferiority when compared with their
comparators (conventional amphotericin B and
liposomal amphotericin B, respectively [44,45]),
whereas voriconazole has not [51]. All were
clearly much better tolerated than conventional
amphotericin B. There is a reasonable expectation
that some of these alternative drugs will make
conventional amphotericin B, with its severe renal
and infusion-related toxicity, an orphan drug.
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